**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 85393

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Delayed referral for liver transplant evaluation worsens outcomes in chronic liver disease patients requiring inpatient transplant evaluation**

Cooper KM *et al*. Delayed LTE worsens outcomes in inpatient LTE

Katherine M Cooper, Alessandro Colletta, Nicholas J Hathaway, Diana Liu, Daniella Gonzalez, Arslan Talat, Curtis Barry, Anita Krishnarao, Savant Mehta, Babak Movahedi, Paulo N Martins, Deepika Devuni

**Katherine M Cooper, Alessandro Colletta, Nicholas J Hathaway, Diana Liu, Daniella Gonzalez,** Department of Medicine, UMass Chan Medical School, Worcester, MA 01605, United States

**Arslan Talat, Curtis Barry, Anita Krishnarao, Savant Mehta, Deepika Devuni,** Department of Medicine, Division of Gastroenterology, UMass Chan Medical School, Worcester, MA 01605, United States

**Babak Movahedi, Paulo N Martins,** Department of Surgery, Transplant Division, UMass Chan Medical School, Worcester, MA 01605, United States

**Author contributions:** Cooper KM, Colletta A, Hathaway NJ, and Devuni D contributed to analysis and interpretation of data; Cooper KM, Talat A, and Devuni D contributed to study concept and design; Cooper KM, Colletta A, Liu D, Gonzalez D, Barry C, Krishnarao A, Mehta S, Movahedi B, and Martins PN contributed to acquisition of data; Cooper KM and Colletta A contributed to drafting of the manuscript; Cooper KM, Martins PN, and Devuni D contributed to critical revision of the manuscript for important intellectual content; Cooper KM and Hathaway NJ contributed to statistical analysis; Barry C, Krishnarao A, Mehta S, Movahedi B, and Martins PN contributed to material support; Devuni D contributed to study supervision.

**Corresponding author: Katherine M Cooper, MD, Doctor,** Department of Medicine, UMass Chan Medical School, 55 Lave Ave North, Worcester, MA 01605, United States. katherine.cooper@umassmed.edu

**Received:** April 25, 2023

**Revised:** May 21, 2023

**Accepted:** June 6, 2023

**Published online:** June 18, 2023

**Abstract**

BACKGROUND

Indications to refer patients with cirrhosis for liver transplant evaluation (LTE) include hepatic decompensation or a model for end stage liver disease (MELD-Na) score ≥ 15. Few studies have evaluated how delaying referral beyond these criteria affects patient outcomes.

AIM

To evaluate clinical characteristics of patients undergoing inpatient LTE and to assess the effects of delayed LTE on patient outcomes (death, transplantation).

METHODS

This is a single center retrospective cohort study assessing all patients undergoing inpatient LTE (*n* = 159) at a large quaternary care and liver transplant center between 10/23/2017-7/31/2021. Delayed referral was defined as having prior indication (decompensation, MELD-Na ≥ 15) for LTE without referral. Early referral was defined as referrals made within 3 mo of having an indication based on practice guidelines. Logistic regression and Cox Hazard Regression were used to evaluate the relationship between delayed referral and patient outcomes.

RESULTS

Many patients who require expedited inpatient LTE had delayed referrals. Misconceptions regarding transplant candidacy were a leading cause of delayed referral. Ultimately, delayed referrals negatively affected overall patient outcome and an independent predictor of both death and not receiving a transplant. Delayed referral was associated with a 2.5 hazard risk of death.

CONCLUSION

Beyond initial access to an liver transplant (LT) center, delaying LTE increases risk of death and reduces risk of LT in patients with chronic liver disease. There is substantial opportunity to increase the percentage of patients undergoing LTE when first clinically indicated. It is crucial for providers to remain informed about the latest guidelines on liver transplant candidacy and the transplant referral process.

**Key Words:** Liver transplantation; Liver transplant evaluation; Liver transplant referral; Patient access; Equity; Patient outcomes

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Cooper KM, Colletta A, Hathaway NJ, Liu D, Gonzalez D, Talat A, Barry C, Krishnarao A, Mehta S, Movahedi B, Martins PN, Devuni D. Delayed referral for liver transplant evaluation worsens outcomes in chronic liver disease patients requiring inpatient transplant evaluation. *World J Transplant* 2023; 13(4): 169-182

**URL:** https://www.wjgnet.com/2220-3230/full/v13/i4/169.htm

**DOI:** https://dx.doi.org/10.5500/wjt.v13.i4.169

**Core Tip:** There are many system and provider-level barriers to liver transplant evaluation. However, the effect of late transplant evaluations remains unclear. We demonstrate delayed liver transplant evaluation is independently associated with death prior to transplant in patients undergoing liver transplant evaluation.

**INTRODUCTION**

The global impact of chronic liver disease is increasing. Liver transplantation is the only definitive treatment for decompensated cirrhosis. Guideline recommended indications to refer patients with cirrhosis for liver transplant evaluation (LTE) include hepatic decompensation or a Model for End Stage Liver Disease score (MELD) ≥ 15[1,2]. While the progression cirrhosis usually occurs over multiple years[3], many patients go un-diagnosed prior to overt hepatic decompensation[3,4]. Thus, many patients have progressed disease when they begin receiving care[5]. Further delays entering the transplant care pathway can result in delayed referral and need for expedited LTE in the setting of acute decompensation. While there is emerging literature on what qualifies as late referral or urgent transplant evaluation[6,7], there is little data regarding the influence of delayed transplant evaluation on outcomes. In this retrospective analysis, we evaluate clinical characteristics of patients undergoing inpatient LTE to identify risk factors for delayed LTE and assess the effect of delayed LTE on patient outcomes.

**MATERIALS AND METHODS**

***Study design and definitions***

This is a single center retrospective cohort study analyzing patients undergoing LTE at a large quaternary care and liver transplant center. Medical records were obtained for patients with a transplant evaluation encounter between October 2017 and July 2021 using our center’s liver transplant database. Patients with diagnosis of cirrhosis who underwent LTE for chronic liver disease (CLD) as an inpatient in this time period were identified as potential subjects. Patients were excluded if they (1) were undergoing re-transplantation; (2) being evaluated for acute liver failure; and (3) were completing evaluation in the outpatient setting. Patients with hepatocellular carcinoma were also excluded due to differences in candidacy and referral criteria[8]. Study data were collected and managed using a 255-field form with an electronic data capture tool hosted at UMass Chan Medical School. Research Electronic Data Capture (REDCap) is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources[9,10].

All clinical and laboratory data including Model for End Stage Liver Disease -Sodium (MELD-Na) score were collected at the time of LTE. Available clinical documentation collected during LTE was closely reviewed and evaluated. Cirrhosis etiologies included chronic alcohol (ETOH) associated liver disease, non-alcoholic steatohepatitis (NASH), Hepatitis C (HCV), cholestatic liver disease (primary sclerosing cholangitis, primary biliary cirrhosis), inherited/genetic disease (hereditary hemochromatosis, alpha-1 anti-trypsin deficiency), and cryptogenic/other. Clinical decompensations included hepatic encephalopathy, jaundice, ascites, hepato-renal syndrome, spontaneous bacterial peritonitis (SBP), and variceal bleed[2,11]. Patients were considered to have a cardiac diagnosis if their past medical history included diagnosis or treatment of a cardiac arrhythmia, coronary artery disease, or cardiomyopathy with heart failure. Malnutrition was diagnosed by registered dieticians on the multidisciplinary transplant team using the ASPEN criteria[12]. Cause of death was recorded when available.

Transplant evaluation indications were defined using the American Association for the Study of Liver Disease (AASLD) guidelines and included (1) hepatic decompensation OR; and (2) MELD ≥ 15 AND 3) absence of active alcohol or illicit drug use[13]. Time for sobriety required for evaluation at our institution is 3 mo. Subjects were dichotomized to either “delayed referral” or “early referral.” “Delayed referral” indicated that subjects had an indication for transplant evaluation but were not referred within three months, while “early referral” meant that subjects were referred within three months of having an indication for transplant evaluation. Three months was chosen as this is the timeline of clinical improvement in patients expected to recover once cirrhosis trigger is withdrawn (*e.g.*, alcohol cessation)[14]. In terms of transplant outcomes, there are multiple potential outcomes of LTE and many of these can occur interchangeably. For example, patients can be approved but not yet listed, or listed but inactive on the wait list. For analytical simplicity, our selected outcomes included: not approved, died on waitlist, off list, on list, and transplanted. For statistical analysis, subjects were further dichotomized as “approved” or “not approved, “dead” or “not dead,” and “transplanted” or “not transplanted” at the time of data collection.

***Endpoints and data analysis***

Normally distributed continuous data is reported as “mean (standard deviation)” and were compared with two-sample *t*-test. Non-normally distributed continuous data is reported as “median [inter-quartile range]” and were compared using Wilcoxon rank sum tests. Categorical variables are reported as “percentage” and were compared using pair-wise z testing. Correlations are reported using Pearson’s bivariate correlation coefficient. Associations are reported as odds ratios with 95% confidence intervals and were evaluated with logistic regression.

Demographic, psychosocial, and clinical variables were compared between delayed and early referral (Tables 1-3). Comparisons were also made between (1) dead and not dead; and (2) transplanted and not transplanted within the delayed referral group to identify potential markers of mortality within this cohort (Supplementary Table 1).

Backward logistic regression modeling was used to identify risk factors for delayed referral with the following starting variables: Age, race, sex, ethnicity, time since diagnosis (months), malnutrition (as defined by ASPEN guidelines), depression, trauma history, number of prior hospitalizations, sobriety period, smoking history, lives with family, married/stable partner, stable housing, employed within 1 year, military service history, non-English first language, education, proximity to transplant center, regular outside gastroenterologist, regular outpatient labs.

Backward logistic regression was also used to evaluate if delayed referral was an independent predictor of transplant status and death amongst other relevant clinical markers (for full list see Tables 4 and 5, respectively). We created a multi-variable logistic regression model utilizing this data and other variables known to affect outcomes in the liver transplantation pathway including but not limited to sex[15], age[16], height[17], acute on chronic liver failure (ACLF) grade[18], and laboratory markers that comprise MELD-Na and represent hepatic function. The final model was created to optimize goodness of fit using the Hosmer and Lemeshow test.

Cox proportional hazard regression modeling was used to evaluate the impact of delayed referral on risk of dead in patients undergoing inpatient LTE. Participants were censored on the day of transplant and the last known well if lost to follow up. An unadjusted model was performed using “delayed” as the sole independent variable; the adjusted model incorporated the following additional variables: age, sex, ethnicity, etiology, MELD-Na, and blood type. Data is reported as hazard ratios (HRs) with 95% confidence intervals.

The threshold for statistical significance was set at *P* values < 0.05. For all backward logistic regression model threshold to enter was 0.05 and threshold to remove was 0.10. All statistical analysis was conducted using SPSS version 29. This study was reviewed and approved by the institutional review board at our medical center.

**RESULTS**

We identified 160 patients undergoing inpatient LTE for cirrhosis (49% delayed referral and 51% early referral). Participants were predominately a male, white, and non-Hispanic with a mean age of 58 +/- 10. Over half of subjects had a high school level education or less (50.7% early *vs* 62.7% delayed, *P* = 0.14). The most common etiologies of cirrhosis were ETOH, NASH, and HCV. Subjects with delayed referral had been diagnosed with liver disease more months on average than those with early referral (*P* < 0.01). Subjects with early referral were diagnosed within the preceding year more often than subjects with delayed referral (50.7% *vs* 30.8%, *P* = 0.02) (See Table 1 for summary of demographics).

Laboratory evaluation collected at time of LTE did not differ between groups (Supplementary Table 2). Most subjects had MELD-Na scores between 25-34 with an average score of 27 in each group (*P* = 0.91). A similar proportion of subjects had Grade 1, Grade 2, and Grade 3 ACLF (*P* = 0.56). The mean number clinical decompensations present during LTE was 4 and the number decompensations positively correlated with MELD-Na score (r(157) = 0.390, *P* < 0.01). One third of subjects were diagnosed with malnutrition during LTE (23.1% delayed referral *vs* 43.9% early referral, *P* ≤ 0.001). Infection was recorded 40% of patients (42.3% delayed *vs* 35.4% early, *P* = 0.39) and blood pressure support occurred in 30% of patients (34.6% delayed *vs* 26.8% early, *P* = 0.29). About half the subjects in each group (48%) required an intensive care unit (ICU) stay during LTE with no differences in days of ICU stay (*P* = 0.44). Trans-jugular intrahepatic portosystemic shunt during admission was 2.3 times more common in delayed referrals (95%CI 0.92-8.25, *P* = 0.11). Most subjects (83%) were accepted as candidates for liver transplant with no differences between groups (*P* = 0.78). However, it took 6-8 d longer to complete LTE for subjects with delayed referral compared to early referral (*P* = 0.07) (See Table 2 for summary of clinical data).

***Pre-LTE: Identifying risk factors for delayed referral***

**Psychosocial factors**: A similar proportion of participants resided with family (*P* = 0.75) and had stable housing in each group (*P* = 0.68). Interestingly more subjects with delayed referral had an established partner compared to early referral (*P* = 0.05). Slightly more subjects with a delayed referral reported English as a second language, though this failed to meet statistical significance 20.5% *vs* 13.6%, *P* = 0.24). In terms of education, almost two thirds of the delayed referral group had a high school education or less compared to one half of the early referral group (*P* = 0.14) Employment within the last year (*P* < 0.01) and having an identifiable source of income (*P* = 0.01) were more common in subjects with early referral. Smoking history (*P* = 0.15) and alcohol use history was similar in each group (*P* = 0.12). However, for those patients who reported prior regular alcohol consumption, early referral subjects were closer to their last drink compared to delayed referral (*P* < 0.01). Specifically, more patients in the early group were evaluated with sobriety of 3-6 mo (39.3% early *vs* 22.4% delayed, *P* = 0.05) while more patents in the delayed group were referred with sobriety of 1-2 years (30.6% delayed *vs* 8.2% early, *P* < 0.01) (See table 3 for summary of psychosocial factors).

**Clinical care- outpatient providers, medication, and gastrointestinal provider notes**: There were no significant differences in pre-LTE hepatic decompensations between groups (Table 3). Average body mass index was slightly higher in missed group (32.5 +/-10 *vs* 30.1 +/- 8; *P* = 0.09). Malnutrition was more common amongst early referrals and was associated with a 2/3 Lower chance of having a delayed referral (OR: 0.34, CI 0.14-0.78, *P* = 0.01). The number of patients receiving routine medications for ascites and hepatic encephalopathy when applicable based on decompensation history did not differ between groups. Interestingly, of the 35.6% of patients with known diabetes, insulin use was more common in delayed referrals, but not to a statistically significant degree (33.3% delayed *vs* 16.7%, *P* = 0.15). Of patients with regular laboratory evaluation available, previously documented hypercoagulability and transaminitis was noted between groups; hypoalbuminemia was slightly more common amongst those with delayed referral (Table 3). Considering only patients with outside documentation from gastroenterologist, there were no differences in proportion of patients with low albumin, elevated international normalized ratio, or abnormal liver enzymes between early and delayed referral (data not shown) (See table 3 for summary of outpatient care factors).

**Risk factors for delayed referrals:** Backward logistic regression model using 20 psychosocial or demographical variables identified female sex and trauma history to be predictors of delayed referral while malnutrition, work within the prior year, and prior smoking history were predictors of early referral (Supplementary Table 3). The most common theme identified in clinical documentation leading to delayed referral was poor understanding about indications for transplant referral, which was identified in 20% of the subjects with delayed referrals. Specifically, outpatient providers cited inaccurate contraindications to transplant, such as age or weight, or incorrect sobriety periods required for referral. Other frequently identified themes included failure to obtain or calculate MELD-Na labs (10%), lack of care continuity (18%), insurance or financial barriers (9%), or patient reluctance to pursue transplant (10%). However, one in three patients had no clear reason for lack of referral.

***Effects of referral time on patient outcomes***

Primary outcome measures differed between those with delayed compared to early referral. Delayed referrals were transplanted less often (28% *vs* 48%) and died prior to transplant more often those with early referral (42% *vs* 21%). Predictors of transplant identified on backward logistic regression include age, ACLF grade, platelets, neutrophil-lymphocyte ratio, albumin, sex, months since diagnosis, weight, blood type, and delayed referral. On a multivariable regression model created using clinical data optimized for goodness of fit, early referral was associated with 2.3 increased odds of receiving a transplant (95%CI: 1.02-4.57; *P* = 0.045) (Supplementary Table 4). Of those transplanted, over 80% of each group was one year post transplant at the time of data collection, and about 50% were two years post-transplant. There were no differences in survival at either the one-year (*P* = 0.650), or two-year (*P* = 1.000) time points (data not shown).

Predictors of death on backward logistic regression include Age, hematocrit, neutrophil to lymphocyte ratio, albumin, months since diagnosis, weight, decompensation number, and delayed referral (Table 5). Within the delayed LTE cohort patients who died were older (*P* = 0.04), had an outpatient gastrointestinal (GI) provider less often (*P* = 0.03), had SBP more often (*P* = 0.04) and required an ICU stay and blood pressure support more often (< 0.01) (Supplementary Table 1). On univariable Cox Regression, the HR of death was 2.2 (95%CI 1.2–2.9) in for delayed referral compared to early referral over average follow up period of 269 d. When adjusting for age, sex, ethnicity etiology, and MELD-Na, the HR for increased to 2.5 (95% 1.3–4.7) for delayed referral compared to early referral (Figure 1).

**DISCUSSION**

Our study assessed clinical characteristics of patients with decompensated cirrhosis undergoing inpatient LTE and examined the effect of delayed referral on patient outcomes. We observed that a significant proportion of patients could have been referred earlier and built on this notion by demonstrated delayed LTE was associated with worse patient outcomes in patients already undergoing urgent LTE. These relationships persisted when controlling for key variables and backward logistic regression identified delayed referral as an independent risk factor for death and not receiving a liver transplant. We identified risk factors for death within the patients who had a delayed LTE to identify the most vulnerable cohorts and found death to be most common in patients with delayed referral and (1) had no regular documentation from an outside GI provider; and (2) were critically ill in the ICU with SBP and requiring blood pressor support.

The high proportion of patients with delayed referrals is consistent with previous studies that report poor adherence to liver transplant referral guidelines in patients with cirrhosis[19]. We sought to identify demographical risk factors for delayed LTE but observed no differences in basic demographics between cohorts in our study*.* Patients in our study resided within similar proximity to the transplant center, which is inconsistent with previous literature reporting that increased distance from a transplant site is a barrier to transplant related care[20]. However, we believe this suggests distance may be more related to the ability to attend health care appointments and not play a role in the referral decision itself. For example, a recent study that identified LTE within 30 d of LT referral was associated with better outcomes and that distance from the transplant center reduced odds of completing LTE within the 30-d window[21]. While we anticipated group differences in health insurance[6,22,23], we observed approximately 50% of each cohort having publicly funding insurance. It is possible that this is due to the robust public health and insurance funding in Massachusetts.

There were notable psychosocial differences between cohorts including education and employment status. Lower education attainment and lack of employment within the preceding year were more common in patients with delayed referral. This data supports that lower degrees of financial stability and health literacy may act as barriers to early evaluation. Identifying patients with limited health literacy could reduce the number of delayed evaluations by improving patients’ understanding of their disease[24]. In addition, we found that being married or having a stable partner was more common in patients with delayed referrals but did not affect transplant or death. We found this point interesting as typically psychosocial support is associated with improved outcomes in the transplant pathway; it remains unclear the role of having a spouse or stable partner on referral and care seeking in this population.

We utilized clinical history and provider written medical documentation to inform understanding of barriers to access to liver transplantation referral and evaluation. First, specific hepatic decompensations did not differ between groups, which is consistent with recent research reporting that clinical manifestations of CLD may be poor markers of the timeliness of transplant evaluation[7]*.* Conversely, malnutrition was protective against of delayed evaluation which may suggest that frailty is a conspicuous manifestation of CLD that is more readily recognized compared to more obscure manifestations of CLD, such as mild hepatic encephalopathy, or that physicians associate frailty with poor outcomes and are more likely to refer. Differences in time from diagnosis to transplant evaluation may reflect this as well, as data suggests providers have different thresholds for referral. Conversely it may be explained by lack of care continuity amongst patients with delayed referrals. Care continuity may reflect poor understanding of disease severity, and it is possible that targeting patient understanding of liver disease may improve the follow up rate in this cohort.

Documentation for 1 in 5 patients with delayed referral included misconceptions about candidacy and referenced inaccurate contraindications to transplant. This was especially evident in subjects with alcohol use disorder, where providers noted longer sobriety periods than truly required to enter the transplant care pathway. These findings are consistent with literature showing provider level factors affect LT access[19,25] and may suggest bias has a negative impact on referral. Patients in our study who were referred within the first year of sobriety had improved outcomes. Patients in the delayed evaluation were more likely to have 1-2 years of sobriety than early referral. Patients who have continued hepatic decompensation after 3 mo of sobriety are less likely to recompensate and our data supports the growing trend for early LTE referral in patients with alcohol liver disease. Our results demonstrate that providers need have increased awareness of patients who have not been referred to a transplant center at this point in sobriety as they may be at increased risk of precipitous decompensation and require urgent LTE. Beyond alcohol, reducing bias toward cirrhosis in general may help as almost one-third of patients did not have an identifiable reason for delayed referral. Further research is needed to characterize referral patterns for LTE. While nationwide and database research can help improve this, there is also the need for regionally based research given practices and attitudes likely vary by geographic location.

We believe our paper has multiple strengths. To our knowledge, this is the first study stratifying inpatient liver transplant candidates based on presence or absence of previously missed opportunities for transplant evaluation and compared outcomes. Study staff had full access to the electronic medical record and were able to conduct a comprehensive chart review that included both discrete/categorical data and more qualitative information from clinical documentation. This offers advantages compared to large databases studies which can analyze large amounts of data, but do not consider the clinical context in which medical decisions are taken. Statistically, we used a variety of modeling methods and used backward logistic regression to demonstrate delayed LTE is an independent predictor of death. This was further supported with Cox regression to demonstrate the strength of this relationship over time.

There are also limitations to our study. Its retrospective and single center nature with a small sample limits the elimination of biases and statistical analysis. Our study population is predominantly white and non-Hispanic which limited our ability to control for the effect of race and ethnicity[26] without disrupting the statistical strength of our models. In effort to account for this, we incorporated language status into the model which improved overall representation of our data*.* This study included evaluations performed during the SARS-2 Coronavirus pandemic, which universally impacted organ transplantation. However, overall patient outcomes did not differ before and after the onset of the pandemic in our study population (data not shown).

In this paper we build on existing literature that demonstrates many patients experience delays in access to LTE care and demonstrate that delayed referral for LTE has a negative impact on patient survival and transplant outcomes even in patients receiving expedited and high-level care at a tertiary liver transplant center. There is substantial opportunity to increase the percentage of patients undergoing transplant evaluation when first clinically indicated. Providers should aim to consistently adhering to referral guidelines to limit provider bias and allow determinations about candidacy to be made by dedicated transplant center. For this to occur, providers need to remain up to date on guidelines regarding liver transplant candidacy, the transplant referral process, and routine work up in patients with CLD. Efforts to increase awareness of this information is critical in general gastroenterology and primary care providers. In future studies, we hope to strengthen the understanding of these phenomena by studying patients who are evaluated through routine outpatient visits.

**CONCLUSION**

Delayed LTE negatively impacts patient care. There are both provider and patient level factors that contribute to delayed LTE and may act as actionable targets to improve patient outcomes.

**ARTICLE HIGHLIGHTS**

***Research background***

Liver transplantation is the only definitive treatment for end stage liver disease, which has an increasing prevalence world wide. Despite this, there are many barriers to accessing liver transplant related care.

***Research motivation***

Barriers to timely liver transplant evaluation (LTE) are poorly understood and likely differ by geographic location.

***Research objectives***

We sought to perform a granular assessment of patients who completed inpatient LTE at our center and to identify risk factors for delayed LTE.

***Research methods***

We performed a single center retrospective cohort study analyzing patients with cirrhosis who completed LTE over 4 years. Patients were categorized as early or delayed LTE based on their clinical history. The electronic medical record was extensively reviewed to identify risk factors for delayed evaluation. Logistic regression was utilized to determine the effect of delayed evaluation on patient outcomes and to identify risk factors for delayed LTE.

***Research results***

Delayed referral increased the risk of death and decreased the odds of receiving a liver transplant. Female sex and trauma history to be predictors of delayed referral while malnutrition, work within the prior year, and prior smoking history were predictors of early referral. Documentation for 1 in 5 patients with delayed referral included misconceptions about candidacy and referenced inaccurate contraindications to transplant.

***Research conclusions***

Many patients undergo delayed LT which is associated with poor patient outcomes. Provider bias and patient psycho-social circumstances are both affect the timeliness of LTE and are targets for interventions aiming to improve access to liver transplantation.

***Research perspectives***

The use of granular data may improve the ability to identify patients at risk at individual centers.

**REFERENCES**

1 **Murray KF**, Carithers RL Jr; AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. *Hepatology* 2005; **41**: 1407-1432 [PMID: 15880505 DOI: 10.1002/hep.20704]

2 **D'Amico G**, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. *J Hepatol* 2022; **76**: 202-207 [PMID: 34157322 DOI: 10.1016/j.jhep.2021.06.018]

3 **Nyberg LM**, Cheetham TC, Patton HM, Yang SJ, Chiang KM, Caparosa SL, Stern JA, Nyberg AH. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. *Hepatol Commun* 2021; **5**: 83-96 [PMID: 33437903 DOI: 10.1002/hep4.1625]

4 **Blais P**, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. *Am J Gastroenterol* 2015; **110**: 10-14 [PMID: 24890441 DOI: 10.1038/ajg.2014.134]

5 **Kwong A**, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Noreen SM, Foutz J, Miller E, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2018 Annual Data Report: Liver. *Am J Transplant* 2020; **20 Suppl s1**: 193-299 [PMID: 31898413 DOI: 10.1111/ajt.15674]

6 **Alshuwaykh O**, Kwong A, Goel A, Cheung A, Dhanasekaran R, Ahmed A, Daugherty T, Dronamraju D, Kumari R, Kim WR, Nguyen MH, Esquivel CO, Concepcion W, Melcher M, Bonham A, Pham T, Gallo A, Kwo PY. Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. *Hepatol Commun* 2021; **5**: 516-525 [PMID: 33681683 DOI: 10.1002/hep4.1644]

7 **Burke L**, Appleby V, Rowe I, Parker R, Jones R. P177 Identifying missed opportunities for transplant assessment: a review of referrals to a liver transplant centre. *BMJ Publishing Group* 2021

8 **Heimbach JK**. Overview of the Updated AASLD Guidelines for the Management of HCC. *Gastroenterol Hepatol (N Y)* 2017; **13**: 751-753 [PMID: 29339953]

9 **Harris PA**, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; **42**: 377-381 [PMID: 18929686 DOI: 10.1016/j.jbi.2008.08.010]

10 **Harris PA**, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019; **95**: 103208 [PMID: 31078660 DOI: 10.1016/j.jbi.2019.103208]

11 **Passi NN**, McPhail MJ. The patient with cirrhosis in the intensive care unit and the management of acute-on-chronic liver failure. *JICS* 2020; **23** [DOI: 10.1177/1751143720978849]

12 **McClave SA**, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, Gervasio JM, Sacks GS, Roberts PR, Compher C; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPEN J Parenter Enteral Nutr* 2016; **40**: 159-211 [PMID: 26773077 DOI: 10.1177/0148607115621863]

13 **Martin P**, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Hepatology* 2014; **59**: 1144-1165 [PMID: 24716201 DOI: 10.1002/hep.26972]

14 **Sberna AL**, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Vergès B, Hillon P, Petit JM. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. *Diabet Med* 2018; **35**: 368-375 [PMID: 29247558 DOI: 10.1111/dme.13565]

15 **Moylan CA**, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. *JAMA* 2008; **300**: 2371-2378 [PMID: 19033587 DOI: 10.1001/jama.2008.720]

16 **Su F**, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, Reyes JD, Ioannou GN. Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. *Gastroenterology* 2016; **150:** 441-53.e6; quiz e16 [PMID: 26522262 DOI: 10.1053/j.gastro.2015.10.043]

17 **Sawinski D**, Lai JC, Pinney S, Gray AL, Jackson AM, Stewart D, Levine DJ, Locke JE, Pomposelli JJ, Hartwig MG, Hall SA, Dadhania DM, Cogswell R, Perez RV, Schold JD, Turgeon NA, Kobashigawa J, Kukreja J, Magee JC, Friedewald J, Gill JS, Loor G, Heimbach JK, Verna EC, Walsh MN, Terrault N, Testa G, Diamond JM, Reese PP, Brown K, Orloff S, Farr MA, Olthoff KM, Siegler M, Ascher N, Feng S, Kaplan B, Pomfret E. Addressing sex-based disparities in solid organ transplantation in the United States - a conference report. *Am J Transplant* 2023; **23**: 316-325 [PMID: 36906294 DOI: 10.1016/j.ajt.2022.11.008]

18 **Finkenstedt A**, Nachbaur K, Zoller H, Joannidis M, Pratschke J, Graziadei IW, Vogel W. Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. *Liver Transpl* 2013; **19**: 879-886 [PMID: 23696006 DOI: 10.1002/lt.23678]

19 **Julapalli VR**, Kramer JR, El-Serag HB; American Association for the Study of Liver Diseases. Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. *Liver Transpl* 2005; **11**: 1370-1378 [PMID: 16184521 DOI: 10.1002/Lt.20434]

20 **Webb GJ**, Hodson J, Chauhan A, O'Grady J, Neuberger JM, Hirschfield GM, Ferguson JW. Proximity to transplant center and outcome among liver transplant patients. *Am J Transplant* 2019; **19**: 208-220 [PMID: 29981195 DOI: 10.1111/ajt.15004]

21 **John BV**, Schwartz K, Scheinberg AR, Dahman B, Spector S, Deng Y, Goldberg D, Martin P, Taddei TH, Kaplan DE. Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System. *Transplantation* 2022; **106**: 72-84 [PMID: 33587434 DOI: 10.1097/TP.0000000000003615]

22 **Bryce CL**, Angus DC, Arnold RM, Chang CC, Farrell MH, Manzarbeitia C, Marino IR, Roberts MS. Sociodemographic differences in early access to liver transplantation services. *Am J Transplant* 2009; **9**: 2092-2101 [PMID: 19645706 DOI: 10.1111/j.1600-6143.2009.02737.x]

23 **Bryce CL**, Chang CC, Angus DC, Arnold RM, Farrell M, Roberts MS. The Effect of Race, Sex, and Insurance Status on Time-to-Listing Decisions for Liver Transplantation. *J Transplant* 2010; **2010**: 467976 [PMID: 21234099 DOI: 10.1155/2010/467976]

24 **Patzer RE**, Adler JT, Harding JL, Huml A, Kim I, Ladin K, Martins PN, Mohan S, Ross-Driscoll K, Pastan SO. A Population Health Approach to Transplant Access: Challenging the Status Quo. *Am J Kidney Dis* 2022; **80**: 406-415 [PMID: 35227824 DOI: 10.1053/j.ajkd.2022.01.422]

25 **M Loy V**, Rzepczynski A, Joyce C, Bello S, Lu A. Disparity in Transplant Referral Patterns for Alcohol-Related Liver Disease Based on Physician-Dependent Variables. *Transplant Proc* 2020; **52**: 900-904 [PMID: 32151390 DOI: 10.1016/j.transproceed.2020.01.015]

26 **McClinton A**, Gullo J, Martins PN, Serrano OK. Access to liver transplantation for minority populations in the United States. *Curr Opin Organ Transplant* 2021; **26**: 508-512 [PMID: 34354000 DOI: 10.1097/MOT.0000000000000904]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the institutional review board at our medical center (IRB Docket: Study00000016, approved 10/24/21).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed care with informed consent. This study received a Health Insurance Portability and Accountability Act (HIPAA) waiver for informed consent at our institution through the IRB review process.

**Conflict-of-interest statement:** All authors have no conflicts of interest related to this study to report.

**Data sharing statement: T**his study was reviewed and approved by the institutional review board at our medical center with a waiver of consent due to the retrospective nature of this study.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Association for the Study of Liver Diseases; Society of Hospital Medicine; American Society of Transplantation; American College of Gastroenterology.

**Peer-review started:** April 25, 2023

**First decision:** May 18, 2023

**Article in press:** June 6, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Li HL, China; Xu X, China **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Multivariable Cox regression model assessing the effect of delayed referral on death when accounting for age, ethnicity, patient sex, MELD score, and disease etiology. Patients were censored if lost to follow up or at the time of transplant.** A: Total survival curve for patients undergoing inpatient liver transplant evaluation (LTE); B: Cox hazard regression output with hazard ratio (HR) with 95% CI and p values are reported from multivariate analysis. (\*) indicates variables that are significant with *P* <0.05; C: Hazard function plotted for risk of death since time of LTE start where “0” is early LTE and “1” is delayed LTE; D: Cumulative survival function since time of LTE start where “0” is early LTE and “1” is delayed LTE. Delayed LTE was associated with increased mortality amongst patients undergoing inpatient LTE.

**Table 1 Baseline and demographics, %**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Delayed referral (*n* = 78)** | **Early referral (*n* = 82)** | ***P* value** |
| Portion of sample | 49 | 51 | - |
| Age (yrs) | 59 (10) | 57 (9) | 0.19 |
| Distance to center (miles) | 43.0 [20.5–59.5] | 43.5 [19.3–67.3] | 0.74 |
| Time since diagnosis (mo) | 30 [12.3–60] | 11 [3.75–55.5] | < 0.01 |
| Gender |  |  | 0.59 |
| Female | 39.7 | 43.9 |  |
| Male | 60.3 | 56.1 |  |
| Race |  |  | 0.49 |
| Asian | 1.3 | 3.7 |  |
| Black or African American | 1.3 | 1.2 |  |
| Other/Unknown | 17.9 | 12.2 |  |
| White | 79.5 | 82.9 |  |
| Ethnicity |  |  | 0.11 |
| Hispanic/other | 19.2 | 9.8 |  |
| Non-Hispanic | 80.8 | 90.1 |  |
| Etiology |  |  | 0.88 |
| Autoimmune | 5.1 | 4.9 |  |
| Alcohol | 43.6 | 53.7 |  |
| Cryptogenic/cholestatic | 5.1 | 6.1 |  |
| Genetic | 7.7 | 4.9 |  |
| Hepatitis C | 11.5 | 9.8 |  |
| NASH | 26.9 | 20.7 |  |
| Blood type |  |  | 0.36 |
| A | 37.2 | 27.2 |  |
| B | 16.7 | 19.8 |  |
| AB | 1.3 | 4.9 |  |
| O | 44.9 | 48.1 |  |

Demographic and clinical data for delayed referral (left) versus early referral (right) patients undergoing inpatient liver transplant evaluation. Data reported as percentages of total group for categorical data; as average (standard deviation) for normally distributed continuous data, and as median [IQR] for non-normally distributed continuous data. NASH: Non-alcoholic steatohepatitis.

**Table 2 Liver transplant evaluation data, %**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Delayed** | **Early** | ***P* value** |
| Transferred to center | 48.7 | 51.2 | 0.75 |
| MELD-Na (points) | 27.2 (7) | 27.0 (9) | 0.87 |
| TIPS placed | 15.4 | 7.3 | 0.22 |
| ICU stay | 51.3 | 43.9 | 0.35 |
| ICU d (#) | 10 (9) | 8 (7) | 0.44 |
| Pressor support | 34.6 | 26.8 | 0.29 |
| Declined for LT listing | 17.9 | 15.9 | 0.72 |
| Reasons declined |  |  |  |
| Psychosocial | 30.0 | 12.5 | 0.38 |
| Medical | 20.0 | 25.0 |
| Death | 30.0 | 12.5 |
| Other | 20.0 | 50.0 |
| Decompensations |  |  |  |
| Ascites | 94.9 | 96.3 | 0.65 |
| Jaundice | 64.1 | 72.0 | 0.29 |
| EVB | 21.8 | 24.4 | 0.70 |
| HE | 70.7 | 70.5 | 0.98 |
| HRS | 59.8 | 62.8 | 0.69 |
| HHT | 21.8 | 14.6 | 0.24 |
| SBP | 21.8 | 18.3 | 0.58 |
| ACLF grade |  |  |  |
| Grade 1 | 34.6 | 42.7 | 0.56 |
| Grade 2 | 50.0 | 42.7 |
| Grade 3 | 15.4 | 14.6 |
| ACLF bilirubin |  |  |  |
| < 15 mg/dL | 82.1 | 76.8 | 0.28 |
| 15-25 mg/dL | 9.0 | 17.1 |
| > 25 mg/dL | 9.0 | 6.1 |
| ACLF INR |  |  |  |
| < 1.8 | 62.8 | 62.2 | 0.78 |
| 1.8-2.5 | 28.2 | 25.6 |
| > 2.5 | 9 | 12.2 |
| ACLF lactate |  |  |  |
| < 1.5 mmol/L | 73.1 | 80.5 | 0.16 |
| 1.5-2.5 mmol/L | 15.4 | 6.1 |
| > 2.5 mmol/L | 11.5 | 13.4 |
| ACLF creatinine |  |  |  |
| < 0.7 mg/dL | 7.3 | 7.3 | 0.64 |
| 0.7-1.5 mg/dL | 32.9 | 32.9 |
| > 1.5 mg/dL | 52.6 | 59.8 |

Clinical data from index admission and liver transplant evaluation. Data reported as percentages of group for categorical data; as average (standard deviation) for normally distributed continuous data. Comparisons were made using students T tests and comparison of proportions test. ACLF: Acute on chronic liver failure; LT: Liver transplant; ICU: Intensive care unit; MELD: Model for end stage liver disease; TIPS: Trans-jugular intrahepatic portosystemic shunt; EVB: Esophagogastric variceal bleeding; HRS: Hepatorenal syndrome; HHT: Hepatic hydrothorax; SBP: Spontaneous bacterial peritonitis; LTE: Liver transplant evaluation; INR: International normalized ratio; HE: Hepatic encephalopathy.

**Table 3 Pre-transplant clinical and demographic factors, %**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Delayed** | **Early** | ***P* value** |
| **Education** |  |  | 0.14 |
| Highschool or less | 62.6 | 50.7 |
| College degree or more | 14.7 | 23.4 |
| **Substance use** |  |  |  |
| Smoking history | 55.1 | 57.3 | 0.15 |
| Drinking history | 62.8 | 74.3 | 0.12 |
| Sobriety period |  |  | < 0.01 |
| < 6 mo | 22.4 | 59.0 |
| 6 mo – 2 yrs | 53.0 | 26.2 |
| > 2 yrs | 23.6 | 14.8 |
| **Psychosocial factors** |  |  |  |
| Depression history | 39.7 | 28.0 | 0.12 |
| Trauma history | 9.0 | 2.4 | 0.07 |
| Public insurance | 50.0 | 50.0 | 1.00 |
| Non-English first language | 20.5 | 13.6 | 0.24 |
| Lives with family | 78.2 | 80.2 | 0.75 |
| Married/stable partner | 67.5 | 52.4 | 0.05 |
| Unstable housing | 6.4 | 4.9 | 0.68 |
| Military service history | 3.8 | 8.6 | 0.21 |
| Worked within 1 mo | 7.7 | 22.2 | <0.01 |
| Worked within 1 yr | 24.4 | 49.4 | <0.01 |
| **Clinical care** |  |  |  |
| Outpatient GI documentation | 83.3 | 78.0% |  |
| Ascites on diuretics | 90.7 | 90.3 | 0.94 |
| Ascites with regular paracentesis | 32.0 | 25.0 | 0.35 |
| On lactulose/rifaximin | 85.0 | 90.5 | 0.39 |
| Midodrine | 42.9 | 46.0 | 0.81 |
| **Regular labs** | *N* = 59 | *N* = 40 |  |
| Low albumin | 89.8 | 77.5 | 0.09 |
| High ALT/AST | 93.2 | 87.5 | 0.31 |
| High INR | 84.7 | 72.5 | 0.14 |
| **Prior decompensations** |  |  |  |
| Ascites | 96.2 | 87.8 | 0.05 |
| Jaundice | 66.7 | 68.3 | 0.83 |
| Variceal bleed | 35.9 | 29.3 | 0.37 |
| Hepatic encephalopathy | 78.2 | 64.2 | 0.06 |
| Hepatorenal syndrome | 35.9 | 31.7 | 0.58 |
| Hepatic hydrothorax | 11.5 | 9.8 | 0.72 |
| Spontaneous bacterial peritonitis | 21.8 | 24.4 | 0.68 |

Comparison of psychosocial and clinical data from prior to liver transplant evaluation (LTE) in patients with delayed compared to early LTE. Psychiatric comorbidities including depression and trauma occurred more in delayed LTE. Working history was strongly associated with timely referral. Data reported as percentages of group for categorical data; as average (standard deviation) for normally distributed continuous data. Comparisons were made using students T tests and comparison of proportions test. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GI: Gastrointestinal; INR: International normalized ratio.

**Table 4 Predictors of transplant**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Initial multivariate regression** | | | | **Backward logistic regression** | | | |
|  | **Wald** | ***P* value** | **OR** | **95%CI** | **Wald** | ***P* value** | **OR** | **95%CI** |
| Age (yr) | 3.45 | 0.06 | 0.94 | 0.9-1.0 | 4.62 | 0.03 | 0.95 | 0.9-1.0 |
| Education (HS) | 2.41 | 0.12 | 1.49 | 0.9-2.5 | - | - | - | - |
| ICU stay (+) | 1.12 | 0.29 | 0.38 | 0.1-2.3 | - | - | - | - |
| ACLF grade (G3) | 2.67 | 0.10 | 2.76 | 0.8-9.3 | 4.75 | 0.03 | 2.13 | 1.1-4.2 |
| MELD (points) | 0.58 | 0.45 | 1.07 | 0.9-1.3 | - | - | - | - |
| Creatinine (mg/dL) | 0.08 | 0.78 | 0.90 | 0.4-1.9 | - | - | - | - |
| Sodium (mmol/L) | 1.28 | 0.26 | 0.90 | 0.8-1.0 | - | - | - | - |
| Bilirubin (mg/dL) | 1.06 | 0.30 | 1.05 | 1.1-1.1 | - | - | - | - |
| INR | 1.28 | 0.26 | 0.42 | 0.1-1.9 | - | - | - | - |
| WBC (×109/L) | 0.03 | 0.86 | 0.99 | 0.8-1.2 | - | - | - | - |
| Hematocrit (%) | 1.34 | 0.25 | 0.94 | 0.9-1.0 | - | - | - | - |
| Platelets (×109/L) | 1.73 | 0.19 | 0.99 | 1.0-1.0 | 5.50 | 0.02 | 0.99 | 1.0-1.0 |
| N-L ratio | 3.65 | 0.06 | 0.89 | 0.8-1.0 | 5.15 | 0.02 | 0.90 | 0.8-1.0 |
| Albumin (g/dL) | 6.79 | < 0.01 | 3.58 | 1.4-9.4 | 9.04 | < 0.01 | 3.32 | 1.5-7.3 |
| Malnutrition (+) | 0.30 | 0.59 | 1.39 | 0.4-4.6 | - | - | - | - |
| Cardiac dx (+) | 0.06 | 0.82 | 0.83 | 0.2-3.9 | - | - | - | - |
| Sex (Male) | 7.29 | < 0.01 | 14.8 | 2.1-105 | 3.02 | 0.08 | 2.38 | 0.9-6.3 |
| Race (White) | 1.24 | 0.27 | 0.42 | 0.1-1.9 | - | - | - | - |
| Depression (+) | 4.17 | 0.04 | 4.24 | 1.1-17 | - | - | - | - |
| Time since dx (mo) | 2.44 | 0.12 | 1.01 | 1.0-1.0 | 2.69 | 0.10 | 1.01 | 1.0-1.0 |
| Pressor need (+) | 0.28 | 0.60 | 0.56 | 0.1-4.8 | - | - | - | - |
| Height (cm) | 2.37 | 0.12 | 0.94 | 0.9-1.0 | - | - | - | - |
| Weight (kg) | 1.22 | 0.27 | 0.99 | 1.0-1.0 | 4.72 | 0.03 | 0.98 | 1.0-1.0 |
| Transferred (+) | 0.00 | 1.0 | 1.00 | 0.3-3.5 | - | - | - | - |
| Refer to LTE (d) | 0.04 | 0.85 | 1.00 | 1.0-1.0 | - | - | - | - |
| **Delayed referral (+)** | 2.67 | 0.10 | 0.32 | 0.1-1.2 | 3.51 | 0.06 | 0.40 | 0.2-1.0 |
| Decompensations (#) | 0.11 | 0.73 | 0.91 | 0.5-1.6 | - | - | - | - |
| Etiology (ETOH) | 0.00 | 0.98 | 1.00 | 0.7-1.5 | - | - | - | - |
| TIPS (+) | 1.36 | 0.24 | 0.52 | 0.2-1.6 | - | - | - | - |
| Blood type (A) | 2.50 | 0.11 | 0.62 | 0.3-1.1 | 2.71 | 0.01 | 0.65 | 0.4-1.1 |
| Constant | 3.26 | 0.07 | 5000 | - | 0.745 | 0.38 | 6.54 | - |

Multivariable logistic model with backward logistic regression to identify predictors of receiving transplant in patients undergoing inpatient liver transplant evaluation (LTE). Starting with 30 potential variables that may predict hepatic encephalopathy, backward regression identified 10 potential independent predictors for transplant including age, ACLF grade, platelets, N-L ratio, serum albumin, sex, time since diagnosis, weight blood type, and having a delayed LTE. Regression complete din SPSS using backward regression conditional model; probability to enter 0.05 and probability to remove 0.10. Units recorded in parenthesis for continuous variables; reference variable recorded in parenthesis for categorical variables where “+” indicates the variable is present in the patient*.* ACLF: Acute on chronic liver failure; ICU: Intensive care unit; WBC: White blood cell count; MELD: Model for end stage liver disease; INR: International normalized ratio; N-L ratio: Neutrophil to lymphocyte ratio; dx: Diagnosis; TIPS: Trans-jugular intrahepatic portosystemic shunt.

**Table 5 Predictors of death**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Initial multivariate regression** | | | | **Backward logistic regression** | | | |
|  | **Wald** | ***P* value** | **OR** | **95%CI** | **Wald** | ***P* value** | **OR** | **95%CI** |
| Age (yrs) | 5.51 | 0.02 | 1.12 | 1.0-1.2 | 6.24 | 0.01 | 1.10 | 1.0-1.1 |
| Education (HS) | 0.72 | 0.40 | 0.75 | 0.4-1.5 | - | - | - | - |
| ICU stay (+) | 0.03 | 0.86 | 0.84 | 0.1-5.8 | - | - | - | - |
| ACLF grade (G3) | 0.06 | 0.81 | 1.19 | 0.3-4.9 | - | - | - | - |
| MELD (points) | 4.58 | 0.03 | 0.73 | 0.5-1.0 | - | - | - | - |
| Creatinine (mg/dL) | 2.85 | 0.09 | 2.46 | 0.9-7.0 | - | - | - | - |
| Sodium (mmol/L) | 5.25 | 0.02 | 0.82 | 0.7-1.0 | - | - | - | - |
| Bilirubin (mg/dL) | 0.04 | 0.84 | 0.99 | 0.9-1.1 | - | - | - | - |
| INR | 3.06 | 0.08 | 8.85 | 0.8-101 | - | - | - | - |
| WBC (×109/L) | 0.02 | 0.88 | 1.02 | 0.8-1.3 | - | - | - | - |
| Hematocrit (%) | 1.57 | 0.21 | 1.11 | 0.9-1.3 | 2.67 | 0.10 | 1.09 | 1.0-1.2 |
| Platelets (×109/L) | 0.09 | 0.76 | 1.00 | 1.0-1.0 | - | - | - | - |
| N-L ratio | 5.90 | 0.02 | 1.22 | 1.0-1.4 | 5.47 | 0.02 | 1.11 | 1.0-1.2 |
| Albumin (g/dL) | 5.07 | 0.02 | 0.18 | 0.0-0.8 | 2.67 | 0.10 | 0.49 | 0.2-1.2 |
| Malnutrition (+) | 0.04 | 0.85 | 0.84 | 0.1-5.1 | - | - | - | - |
| Cardiac dx (+) | 1.71 | 0.19 | 3.53 | 0.5-23 | - | - | - | - |
| Sex (Male) | 4.43 | 0.04 | 0.08 | 0.0-0.8 | - | - | - | - |
| Race (White) | 1.06 | 0.30 | 0.32 | 0.0-2.8 | - | - | - | - |
| Depression (+) | 1.72 | 0.19 | 3.07 | 0.6-16 | - | - | - | - |
| Time since dx (mo) | 5.84 | 0.02 | 0.97 | 1.0-1.0 | 3.52 | 0.06 | 0.99 | 1.0-1.0 |
| Pressor need (+) | 0.36 | 0.55 | 0.44 | 0.0-6.5 | - | - | - | - |
| Height (cm) | 4.04 | 0.05 | 1.13 | 1.0-1.3 | - | - | - | - |
| Weight (kg) | 3.83 | 0.05 | 1.04 | 1.0-1.1 | 7.01 | < 0.01 | 1.02 | 1.0-1.0 |
| Transferred (+) | 1.53 | 0.22 | 0.36 | 0.1-1.8 | - | - | - | - |
| Refer to LTE (d) | 0.65 | 0.42 | 0.99 | 1.0-1.0 | - | - | - | - |
| Delayed referral (+) | 6.75 | 0.01 | 8.40 | 1.7- 42 | 7.27 | < 0.01 | 4.51 | 1.5-14 |
| Decompensations (#) | 3.61 | 0.06 | 2.08 | 1.0-4.4 | 6.33 | 0.01 | 1.49 | 1.1-2.0 |
| Etiology (ETOH) | 1.22 | 0.27 | 1.30 | 0.8-2.1 | - | - | - | - |
| Blood type (A) | 4.98 | 0.03 | 3.01 | 1.1-7.9 | - | - | - | - |
| TIPS (+) | 0.44 | 0.51 | 1.45 | 0.5-4.4 | - | - | - | - |
| Constant | 0.09 | 0.76 | 0.02 | - | 0.75 | 0.38 | 6.54 | - |

Multivariable logistic model with backward logistic regression to identify predictors of receiving transplant in patients undergoing inpatient liver transplant evaluation (LTE). Starting with 30 potential variables that may predict hepatic encephalopathy, backward regression identified 8 potential independent predictors for transplant including age, Hematocrit, N-L ratio, serum albumin, sex, time since diagnosis, weight, number of decompensations, and having a delayed LTE. Regression complete din SPSS using backward regression conditional model; probability to enter 0.05 and probability to remove 0.10. Units recorded in parenthesis for continuous variables; reference variable recorded in parenthesis for categorical variables where “+” indicates the variable is present in the patient*.* ACLF: Acute on chronic liver failure; ICU: Intensive care unit; WBC: White blood cell count; MELD: Model for end stage liver disease; INR: International normalized ratio; N-L ratio: Neutrophil to lymphocyte ratio; dx: Diagnosis; TIPS: Trans-jugular intrahepatic portosystemic shunt.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**